A032101
|
Alliance
|
A Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): A-DREAM
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
A032102
|
Alliance
|
PREcision DIagnostics in Prostate Cancer Treatment (PREDICT)
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
A032103
|
Alliance
|
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
A032201
|
Alliance
|
Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-Risk Renal Cell Carcinoma - STRIKE
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
A032303
|
Alliance
|
GAIN-BCG: Gemcitabine Alternating with INtravesical BCG Randomized Against BCG Alone for Patients with Recurrent High Grade Non-Muscle Invasive Bladder Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
A041202
|
Alliance
|
A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (>/= 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
A041501
|
Alliance
|
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (A Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
A041701
|
Alliance
|
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
A041702
|
Alliance
|
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
A041703
|
Alliance
|
Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|